Favipiravir is a selective and potent inhibitor of influenza viral RNA polymerase. It acts as
a purine analogue, which selectively inhibits viral RNA-dependent RNA polymerase (RdRps). It
has the characteristic of acting on RNA viruses including Ebola and Coronaviruses especially
novel coronavirus (2019-nCoV). The purpose of this study is to evaluate the clinical efficacy
and safety of Favipiravir in comparison to placebo in the treatment of mild COVID-19 cases.
It is a Multicenter, randomized double-blinded, parallel-group trial.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
King Abdullah International Medical Research Center